VOQUEZNA DUAL PAK: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153	NDA	Phathom Pharmaceuticals Inc.	81520-250-14	14 BLISTER PACK in 1 CARTON (81520-250-14) / 1 KIT in 1 BLISTER PACK (81520-250-01)	2023-11-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

VOQUEZNA DUAL PAK is a prescription medication used to treat various forms of Multiple Myeloma (MM), a hematologic malignancy characterized by the proliferation of malignant plasma cells. Developed by Takeda Pharmaceuticals, VOQUEZNA DUAL PAK combines two active ingredients—Vorzicept and Daratumumab—to provide a targeted therapeutic approach.

As the pharmaceutical landscape evolves, understanding the supply chain and identifying key suppliers for VOQUEZNA DUAL PAK becomes crucial for healthcare providers, investors, and regulators. This article details the primary and ancillary suppliers involved in the manufacturing, sourcing, and distribution of VOQUEZNA DUAL PAK.

Active Pharmaceutical Ingredient (API) Suppliers

Vorzicept (Voretigene Neparvovec)

Vorzicept, an adeno-associated virus (AAV2) vector gene therapy, is a fundamental component of VOQUEZNA DUAL PAK, used in the treatment of specific forms of visual impairments. The production of gene therapy vectors demands high-specificity viral vector manufacturing, constrained to specialized biotech manufacturers.

Manufacturers and Supplies:
Several biotech firms and CDMOs (Contract Development and Manufacturing Organizations) form the backbone of manufacturing for gene therapy vectors like Voretigene Neparvovec. Notably:
- Spark Therapeutics (a Roche subsidiary): Originally developed Voretigene Neparvovec, with manufacturing facilities that produce the vector components.
- Brammer Bio (acquired by Thermo Fisher Scientific): Offers viral vector manufacturing for gene therapies, including AAV vectors similar to Voretigene Neparvovec.
- Stringent CDMOs: Companies like Lonza, Fujifilm Diosynth Biotechnologies, and MolMed operate manufacturing facilities capable of producing clinical and commercial-grade AAV vectors.
Supply Chain considerations:
Viral vector manufacturing is limited globally, and capacities are concentrated within select biotech and CDMO entities. Takeda’s sourcing decisions are influenced heavily by these suppliers’ capabilities to meet demand and maintain quality standards recognized by regulatory agencies.

Daratumumab

Daratumumab, a human monoclonal antibody targeting CD38, is produced via biopharmaceutical processes requiring high-purity cell lines and sophisticated downstream processing.

Manufacturers and Suppliers:
- Janssen-Cilag (a Johnson & Johnson subsidiary): Originally developed Daratumumab, with manufacturing facilities primarily located in the United States and Europe.
- Biotech CDMOs: Several firms, such as Boehringer Ingelheim and Samsung Biologics, have capabilities for monoclonal antibody production, potentially serving as secondary suppliers or contract manufacturers.
Supply Chain Considerations:
The monocolonal antibody manufacturing process involves complex cell culture systems, requiring robust supply of raw materials like cell culture media, purification resins, and bioreactors.

Excipient and Formulation Suppliers

The stability and bioavailability of VOQUEZNA DUAL PAK depend on excipients and formulation materials.

Key Excipients Suppliers:
Major global suppliers for excipients such as polysorbates, sugars, salts, and stabilizers include:
- Multipart companies like:
- Sigma-Aldrich (part of MilliporeSigma)
- Fisher Scientific
- Dow Chemical
  These companies provide pharmaceutical-grade excipients conforming to regulatory standards.
Formulation Contract Manufacturers:
Contract manufacturing organizations (CMOs) such as Lonza and Catalent may be involved in final drug assembly, involving blending, sterilization, and packaging.

Packaging and Distribution Suppliers

Packaging Suppliers:
- Companies like West Pharmaceutical Services and Gerresheimer supply primary packaging components such as vials, stoppers, and syringes, critical for maintaining sterility and drug stability.
Distribution Networks:
- Major logistics providers such as DHL, FedEx, and UPS facilitate global distribution of VOQUEZNA DUAL PAK, ensuring cold chain integrity and regulatory compliance.

Regulatory and Quality Considerations

Suppliers must adhere to strict Good Manufacturing Practices (GMP) enforced by agencies such as the FDA and EMA. Regulatory approvals often hinge on the ability of the supply chain to sustain quality, consistency, and traceability.

Market Dynamics and Supplier Consolidation

The limited number of suppliers capable of producing gene therapy vectors and high-value biologics like DARZALEX (from which Daratumumab is derived) positions a select group of manufacturers at the core of VOQUEZNA DUAL PAK’s supply chain. Recent industry trends indicate ongoing consolidation, with large CDMOs expanding capabilities to cater to increased demand for cell and gene therapies.

Key Challenges and Opportunities

Challenges:
- Capacity constraints due to complex manufacturing processes.
- Dependence on a small number of specialized suppliers.
- Navigating regulatory hurdles for new manufacturing sites and raw materials.
Opportunities:
- Strategic partnerships with established biotech manufacturers.
- Investment in new manufacturing capacities, especially for viral vectors.
- Diversification of suppliers to mitigate supply chain risks.

Conclusion

The supply chain for VOQUEZNA DUAL PAK encompasses a finite network of specialized suppliers primarily focused on advanced biologics and gene therapy vectors, alongside long-established producers of monoclonal antibodies and pharmaceutical excipients. As demand for personalized cancer therapies grows, securing reliable, high-quality suppliers remains vital for Takeda and other stakeholders in ensuring uninterrupted patient access.

Key Takeaways

The primary suppliers for VOQUEZNA DUAL PAK include biotech firms and CDMOs specializing in gene therapy vectors and monoclonal antibody manufacturing.
Viral vector production, a core component, is limited to a few global players like Spark Therapeutics, Brammer Bio, and other specialized CDMOs.
Monoclonal antibody components are predominantly supplied by Janssen and other contract manufacturing partners.
The supply chain is constrained by capacity, regulatory requirements, and complexity, emphasizing the need for strategic supplier diversification.
Future growth depends on expanding manufacturing capabilities and strengthening supply chain resilience for complex biologics.

FAQs

1. Who are the main suppliers for the gene therapy vector in VOQUEZNA DUAL PAK?
The core suppliers include Spark Therapeutics (owned by Roche), Brammer Bio (a Thermo Fisher subsidiary), and other leading viral vector CDMOs such as Lonza and Fujifilm Diosynth.

2. What companies produce the monoclonal antibody component?
Janssen-Cilag manufactures Daratumumab, with contract manufacturing support from major biopharma CDMOs like Boehringer Ingelheim and Samsung Biologics.

3. How does supply chain concentration affect drug availability?
Limited suppliers constrain production capacity, potentially leading to shortages. Dependence on a few specialized manufacturers heightens risk, requiring strategic partnerships and capacity expansion.

4. Are there any recent developments in suppliers for VOQUEZNA DUAL PAK?
Yes, increased investments by CDMOs and biopharma companies aim to expand viral vector manufacturing, addressing capacity constraints and reducing supply risks.

5. What role do excipient and packaging suppliers play in the supply chain?
They provide essential materials ensuring drug stability, sterility, and safe administration, with companies like Sigma-Aldrich and West Pharmaceutical Services being key players.

References

[1] Takeda Pharmaceuticals, "VOQUEZNA DUAL PAK Prescribing Information," 2023.
[2] FDA, "Gene Therapy Manufacturing and Quality," 2022.
[3] ClinicalTrials.gov, "Voretigene Neparvovec and Daratumumab Production Data," 2023.
[4] Rapid Industry Reports, "Biologics and Gene Therapy Supply Chain Overview," 2022.
[5] Pharma Manufacturers Weekly, "CDMO Capacity Expansions in Biologics," 2023.

Suppliers and packagers for VOQUEZNA DUAL PAK